AXP
63
3
PPL
44
9
AMT
30
2
LEN
21
3
VFC
56
6
URBN
67
3
NDAQ
46
2
TRV
34
4
F
38
4
FTI
61
5
MAR
57
3
EIX
61
8
GWW
50
9
UNH
42
6
IP
53
3
TXN
29
4
CCI
30
2
PRU
39
3
HD
43
8
MDT
59
4
AXP
63
3
PPL
44
9
AMT
30
2
LEN
21
3
VFC
56
6
URBN
67
3
NDAQ
46
2
TRV
34
4
F
38
4
FTI
61
5
MAR
57
3
EIX
61
8
GWW
50
9
UNH
42
6
IP
53
3
TXN
29
4
CCI
30
2
PRU
39
3
HD
43
8
MDT
59
4
Financhill
Back

Avid Bioservices 10K Form

Buy
56

CDMO
Avid Bioservices

Last Price:
$12.31
Seasonality Move:
76.3%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CDMO News And Ratings

See the #1 stock for the next 7 days that we like better than CDMO

CDMO Financial Statistics

Sales & Book Value

Annual Sales: $139.9M
Cash Flow: $547K
Price / Cash Flow: 0
Annual Sales: $0.70
Price / Book: 17.59

Profitability

EPS (TTM): -2.39000
Net Income (TTM): $-152.1M
Gross Margin: $7.3M
Return on Equity: -143.94%
Return on Assets: -39.92%

Avid Bioservices Earnings Forecast

Key Avid Bioservices Financial Ratios

  • The Gross Profit Margin over the past 30 years for CDMO is 5.23%.
  • The Selling, General & Administrative Expenses for CDMO have been equal to 18.58% of Gross Profit Margin.
  • The Research & Development expenses have been 49.11% of Revenue.
  • The Interest Expense is -3.08% of Operating Income.
  • The Net Earning history of CDMO is -100.60% of Total Revenues.
  • Per Share Earnings over the last 30 years have been positive in 19 years.

Avid Bioservices Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: CDMO
CUSIP: 05368M
Website: avidbio.com

Debt

Debt-to-Equity Ratio: 3.44
Current Ratio: 1.3
Quick Ratio: 0.86

Price-to-Earnings

Trailing P/E Ratio: 1573.5
Forward P/E Ratio: 410.67

CDMO Technical Analysis vs Fundamental Analysis

Buy
56
Avid Bioservices (CDMO) is a Buy

Is Avid Bioservices a Buy or a Sell?

  • Avid Bioservices stock is rated a Buy
    The current Avid Bioservices [CDMO] share price is $12.32. The Score for CDMO is 56, which is 12% above its historic median score of 50, and infers lower risk than normal.